Neurotoxicity in adult patients with cystic fibrosis using polymyxin B for acute pulmonary exacerbations.
Nick RekisMadelaine AmbroseColleen M SakonPublished in: Pediatric pulmonology (2020)
We present four case reports that describe neurotoxicity experienced in adult patients with cystic fibrosis (CF) receiving intravenous polymyxin B. Paresthesia was observed after the first dose of polymyxin B in all patients. These symptoms resolved after discontinuation of polymyxin B and switching treatment to colistin. All four patients completed therapy with colistin without experiencing additional adverse reactions. This report contributes to the small body of literature currently available on the use of polymyxin B in the CF population.
Keyphrases
- cystic fibrosis
- gram negative
- end stage renal disease
- pseudomonas aeruginosa
- ejection fraction
- chronic kidney disease
- escherichia coli
- multidrug resistant
- chronic obstructive pulmonary disease
- drug resistant
- stem cells
- lung function
- emergency department
- acinetobacter baumannii
- liver failure
- mesenchymal stem cells
- klebsiella pneumoniae
- case report
- air pollution
- drug induced